E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic kidney disease (CKD) |
Enfermedad renal cronica (ERC) |
|
E.1.1.1 | Medical condition in easily understood language |
Renal Disease: A gradual loss of kidney function leading to insufficient filtration of waste and excess fluid from the blood |
Enfermedad Renal: Pérdida gradual de la función renal que conduce a una filtración insuficiente de residuos y pérdida excesiva de fluidos en sangre |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of ≥50% sustained decline in estimated glomerular filtration rate (eGFR), reaching end stage renal disease (ESRD), CV or renal death when added to current background therapy in patients with eGFR ≥25 and ≤75 mL/min/1.73m2 and albuminuria (urine albumin creatinine ratio [UACR] ≥200 and ≤5000 mg/g) |
Determinar si dapagliflozina es superior frente al placebo reduciendo la incidencia de la variable primaria compuesta en la disminución sostenida de ≥50% en la tasa de filtración glomerular estimada (TFGe), alcanzando la enfermedad renal en etapa terminal (ERET), muerte cardiovascular o renal cuando se añade a la terapia actual basal en pacientes con TFGe ≥25 y ≤75 mL/min/1.73m2 y albuminuria (cociente albúmina/creatinina en orina [ACR] ≥200 y ≤5000 mg/g) |
|
E.2.2 | Secondary objectives of the trial |
1) To determine whether dapagliflozin compared with placebo will result in a reduction of the incidence of the composite endpoints of worsening of renal function
2) To determine whether dapagliflozin compared with placebo will result in a reduction of the incidence of the composite endpoint of CV death or hospitalization for heart failure
3) To determine whether dapagliflozin compared with placebo will result in a reduction of the incidence of all-cause mortality
4) Safety Objective: To evaluate the safety and tolerability of dapagliflozin in this patient population |
1) Determinar si dapagliflozina en comparación con placebo dará como resultado una reducción de la incidencia de las variables compuestas en el empeoramiento de la función renal.
2) Determinar si dapagliflozina en comparación con el placebo dará lugar a una reducción de la incidencia de las variables compuestas de muerte cardiovascular u hopitalización por insuficiencia cardíaca
3) Determinar si dapagliflozina en comparación con placebo dará como resultado una reducción en la incidencia de la mortalidad por cualquier causa.
4) Objetivo de Seguridad: Evaluar la seguridad y tolerabilidad de dapagliflozina en esta población de pacientes
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Provision of signed informed consent prior to any study specific procedures
• Female or male aged ≥18 years at the time of consent
• eGFR ≥25 and ≤75 mL/min/1.73m2 (CKD-EPI Formula)
• UACR ≥200 and ≤5000 mg/g at visit 1
• Stable, and for the patient maximum tolerated labelled daily dose, treatment with ACE-I or ARB for at least 4 weeks before visit 1, if not medically contraindicated |
• Provisión de los consentimientos informados firmados antes de cualquier procedimiento específico de estudio
• Hombre o mujer mayores≥18 años en el momento del consentimiento
• TFGe ≥25 y ≤75 mL/min/1.73m2 (Ecuación CKD-EPI)
• UACR ≥200 y ≤5000 mg/g en visita 1
• Dosis máxima diaria tolerada y estable de tratamiento con IECA o ARA al menos 4 semanas antes de su primera visita, si no está clínicamente contraindicada. |
|
E.4 | Principal exclusion criteria |
• Autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis
• Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment
• History of organ transplantation
• Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
• Type 1 diabetes mellitus
• New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment
• MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment |
• Enfermedad renal políquistica autosómica dominante o autosómica recesiva, nefritis lúpica o vasculitis asociadas a ANCA
• Pacientes que estén recibiendo tratamiento citotóxico, inmunosupresores u otra inmunoterapia para la enfermedad renal primaria o secundaria dentro de los primeros 6 meses antes de la inclusión
• Antecedentes de trasplante de órganos
• Pacientes que estén recibiendo tratamiento de inhibidores de SGLT2 dentro de las 8 semanas antes de la inclusión o intolerancia anterior a los inhibidores de SGLT2
• Diabetes Mellitus Tipo 1
• Clase IV Insuficiencia Cardiovascular Congestiva según la escala NYHA (New York Heart Association) en el momento de la inclusión
• IM, accidente cerebrovascular o ataque isquémico transitorio dentro de las 12 semanas anteriores a la inclusión
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to the first occurrence of any of the components of this composite:
1. ≥50% sustained decline in eGFR
2. Reaching ESRD
- Sustained eGFR <15 mL/min/1.73m2 or,
- Chronic dialysis treatment or,
- Receiving a renal transplant
3. CV death
4. Renal death |
Tiempo hasta la primera aparición de alguno de los componentes de este conjunto:
1. ≥50% disminución sostenida del TFGe
2. Alcanzar ERET
- TFGe sostenida <15 mL/min/1.73m2 o,
- Tratamiento de diálisis crónica o,
- Transplante de órganos recibido
3. Muerte CV
4. Muerte Renal |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint will be evaluated when at least 100% of the primary events are adjudicated, which means at 681 adjudicated primary events. |
La variable principal será evaluada cuando al menos el 100% de los eventos primarios hayan sido adjudicados, lo que implica 681 eventos primarios adjudicados. |
|
E.5.2 | Secondary end point(s) |
1) Time to the first occurrence of any of the components of this composite:
1. ≥50% sustained decline in eGFR
2. Reaching ESRD
3. Renal death
2) Time to the first occurrence of either of the components of this composite:
1. CV death
2. Hospitalization for heart failure
3) Time to death from any cause
4) Safety endpoints:
1. Serious adverse event (SAE)
2. Discontinuation of investigational product (IP) due to adverse event (DAE)s
3. Changes in clinical chemistry/haematology parameters
4. AEs of interest (volume depletion, renal events, major hypoglycaemic events, fractures, diabetic ketoacidosis (DKA) and AEs leading to amputation) |
1) Tiempo hasta la primera aparición de alguno de los componentes de este conjunto:
1. ≥50% disminución sostenida del TFGe
2. Alcanzar ERET
3. Muerte Renal
2) Tiempo hasta la primera aparición de cualquiera de los componentes de este conjunto:
1. Muerte CV
2. Hospitalización por insuficiencia cardíaca
3) TIempo hasta fallecimiento por cualquier causa.
4) Variables de seguirdad:
1. Acontecimiento Adverso Grave (SAE)
2. Interrupción del medicamento en investigación (MI) debido a un acontecimiento adverso (DAE)s
3. Cambios en los parámetros clínicos químicos/hematológicos
4. AEs de interés (depleción de volumen, acontecimientos renales, acontecimientos importantes de hipoglucemia, fracturas, cetoacidosis diabética (DKA) y AEs que conducen a una amputación) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will only be evaluated once – and that is when the study stops, when at least 100% of the primary events are adjudicated. |
Las variables secundarias serán evaluadas sólo una vez- en este momento será cuando el estudio finalizará, cuando al menos el 100% de los eventos primarios hayan sido adjudicados. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 105 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Brazil |
Canada |
China |
Denmark |
Germany |
Hungary |
India |
Korea, Republic of |
Mexico |
Peru |
Philippines |
Poland |
Russian Federation |
Spain |
Sweden |
Ukraine |
United Kingdom |
United States |
Vietnam |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit of the last patient undergoing the study. |
La última visita del último paciente que se encuentre en el estudio. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |